Skip to main content
. 2020 May 7;10:45. doi: 10.1186/s13550-020-00635-z

Fig. 6.

Fig. 6

[99mTc]Tc-PSMA-I&S-SPECT/CT of a 71-year-old patient with mCRPC and disease progression and severe fatigue after the second cycle of chemotherapy (docetaxel). a Pretherapeutic tumor spread in paraaortic and pelvic lymph nodes (PSA 335 ng/ml). b Restaging 3 months after 2 cycles of 177Lu-PSMA therapy (PSA 0.6 ng/ml). [99mTc]Tc-PSMA-I&S-SPECT/CT was negative